Jill Lacy

8.5k total citations · 1 hit paper
117 papers, 3.3k citations indexed

About

Jill Lacy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jill Lacy has authored 117 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Oncology, 43 papers in Pulmonary and Respiratory Medicine and 25 papers in Cancer Research. Recurrent topics in Jill Lacy's work include Pancreatic and Hepatic Oncology Research (38 papers), Colorectal Cancer Treatments and Studies (25 papers) and Cancer Genomics and Diagnostics (24 papers). Jill Lacy is often cited by papers focused on Pancreatic and Hepatic Oncology Research (38 papers), Colorectal Cancer Treatments and Studies (25 papers) and Cancer Genomics and Diagnostics (24 papers). Jill Lacy collaborates with scholars based in United States, France and Spain. Jill Lacy's co-authors include David Coleman, Howard S. Höchster, Stacey Stein, John R. Murren, R. Bernd Sterzel, Jaykumar Thumar, Giovanni Tallini, Jill Crouch, E Salloum and M. Schultz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Jill Lacy

111 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

2016 653 citations Mustafa Suker, Eran Sadot et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jill Lacy United States	27	2.2k	807	682	643	531	117	3.3k
Annette Ramaswamy Germany	35	1.8k 0.8×	652 0.8×	725 1.1×	586 0.9×	1.2k 2.3×	110	3.7k
Yoshihiko Hoshida Japan	35	1.3k 0.6×	357 0.4×	355 0.5×	491 0.8×	1.3k 2.4×	117	3.3k
Tilmann Spieker Germany	25	913 0.4×	346 0.4×	678 1.0×	285 0.4×	928 1.7×	61	2.8k
Thomas Klingebiel Germany	31	959 0.4×	988 1.2×	280 0.4×	351 0.5×	557 1.0×	90	3.2k
Michael Dictor Sweden	34	1.7k 0.8×	402 0.5×	341 0.5×	279 0.4×	1.1k 2.0×	97	3.4k
Roman Kodet Czechia	31	964 0.4×	815 1.0×	316 0.5×	251 0.4×	1.3k 2.4×	171	3.1k
K Aozasa Japan	28	1.5k 0.7×	481 0.6×	268 0.4×	326 0.5×	541 1.0×	71	2.8k
Makio Mukai Japan	37	1.2k 0.5×	2.0k 2.5×	594 0.9×	576 0.9×	1.2k 2.2×	176	4.7k
Kiyoshi Mukai Japan	29	2.0k 0.9×	552 0.7×	524 0.8×	426 0.7×	796 1.5×	87	3.1k
Yukichi Tanaka Japan	31	977 0.4×	1.1k 1.3×	360 0.5×	539 0.8×	1.8k 3.4×	187	4.2k

Countries citing papers authored by Jill Lacy

Since Specialization

Citations

This map shows the geographic impact of Jill Lacy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jill Lacy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jill Lacy more than expected).

Fields of papers citing papers by Jill Lacy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jill Lacy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jill Lacy. The network helps show where Jill Lacy may publish in the future.

Co-authorship network of co-authors of Jill Lacy

This figure shows the co-authorship network connecting the top 25 collaborators of Jill Lacy. A scholar is included among the top collaborators of Jill Lacy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jill Lacy. Jill Lacy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Su, David, Beatrice J. Sun, Kiran K. Turaga, et al.. (2025). Consensus guideline for the management of gastric cancer with synchronous peritoneal metastases. Cancer. 131(13). e35870–e35870.

Uhlig, Johannes, Joanna Gibson, Michael Cecchini, et al.. (2024). Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms. Scientific Reports. 14(1). 30536–30536. 5 indexed citations

Cecchini, Michael, Janie Y. Zhang, Wei Wei, et al.. (2023). Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer Research Communications. 3(6). 1132–1139. 4 indexed citations

Lacy, Jill, Michael Cecchini, Jeremy Kortmansky, et al.. (2023). Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer. Journal of Gastrointestinal Oncology. 14(3). 1181–1192. 3 indexed citations

Patel, Timil, Joseph A. Miccio, Michael Cecchini, et al.. (2021). Clinical outcomes of first line FOLFIRINOX vs. gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System. Journal of Gastrointestinal Oncology. 12(6). 2547–2556. 3 indexed citations

Coleman, Emily, Gauri Panse, Shawn E. Cowper, Jill Lacy, & Jonathan S. Leventhal. (2019). Disappearing pigmentary mosaicism during imatinib treatment for gastrointestinal stromal tumors. JAAD Case Reports. 5(2). 170–172. 2 indexed citations

Curtis, Brian R., Yen‐Michael S. Hsu, Nikolai A. Podoltsev, et al.. (2017). Drug-Induced Immune Thrombocytopenia (DITP) Caused By Multiple Drug-Dependent Platelet-Reactive Antibodies (DDAbs) in Patients Undergoing Oxaliplatin-Containing Combination Chemotherapy for Metastatic Colon Cancer. Blood. 130. 3625–3625.

Philip, P. A., Jill Lacy, Alberto F. Sobrero, et al.. (2017). nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial. Annals of Oncology. 28. v212–v212. 2 indexed citations

Hammel, Pascal, Jill Lacy, Fabienne Portales, et al.. (2016). P-272 The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced pancreatic cancer (LAPC). Annals of Oncology. 27. ii78–ii78. 1 indexed citations

10.

Suker, Mustafa, Eran Sadot, Lysiane Marthey, et al.. (2016). A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer. HPB. 18. e342–e343. 5 indexed citations

11.

Stein, Stacey, Edward James, Yanhong Deng, et al.. (2016). Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. British Journal of Cancer. 114(7). 737–743. 153 indexed citations

12.

Halene, Stephanie, et al.. (2014). Oxaliplatin-Related Acute Disseminated Intravascular Coagulation Syndrome in a Patient With Metastatic Colon Cancer. Clinical Colorectal Cancer. 14(1). e9–e12. 6 indexed citations

13.

Gunturu, Krishna S., Xiaopan Yao, Xiangyu Cong, et al.. (2012). FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Medical Oncology. 30(1). 361–361. 115 indexed citations

14.

Lacy, Jill, et al.. (2012). Complications of Brain Tumors and Their Treatment. Hematology/Oncology Clinics of North America. 26(4). 779–796. 27 indexed citations

15.

Burtness, Barbara, Michael K. Gibson, Brian L. Egleston, et al.. (2009). Phase II trial of docetaxel–irinotecan combination in advanced esophageal cancer. Annals of Oncology. 20(7). 1242–1248. 23 indexed citations

16.

Burtness, Barbara, Ronald R. Salem, Robert Kloss, et al.. (2007). Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer. The Cancer Journal. 13(4). 257–262. 20 indexed citations

17.

Lacy, Jill, et al.. (2006). Systemic Bcl‐2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV⁺ nasopharyngeal carcinoma xenografts in SCID mice. International Journal of Cancer. 119(2). 309–316. 15 indexed citations

18.

Goldstein, Nathaniel B., et al.. (1999). Treatment of EBV transformed tumors with antisense oligodeoxynucleotides against EBNA-1 enhances tumor chemosensitivity. 4(4). 278–286. 1 indexed citations

19.

Piepmeier, Joseph M., Dennis D. Spencer, Thomas N. Byrne, et al.. (1996). Variations in the History and Survival of Patients with, Supratentorial Low-grade Astrocytomas. Neurosurgery. 38(5). 872–879. 198 indexed citations

20.

Ruef, Christian, Klemens Budde, Jill Lacy, et al.. (1990). Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney International. 38(2). 249–257. 174 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact